Henan Lingrui Pharmaceutical Co Ltd (600285) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Henan Lingrui Pharmaceutical Co Ltd (600285) has a cash flow conversion efficiency ratio of 0.043x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥140.12 Million ≈ $20.50 Million USD) by net assets (CN¥3.28 Billion ≈ $480.45 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Henan Lingrui Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Henan Lingrui Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Henan Lingrui Pharmaceutical Co Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Henan Lingrui Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Henan Lingrui Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AddLife AB (publ)
ST:ALIF-B
|
0.163x |
|
Tongyu Heavy Industry
SHE:300185
|
0.004x |
|
OFG Bancorp
NYSE:OFG
|
0.028x |
|
Lingyun Ind
SHG:600480
|
0.044x |
|
Stanley Fertilizer Co Ltd
SHE:002588
|
0.134x |
|
Cupid Limited
NSE:CUPID
|
0.061x |
|
Netac Tech
SHE:300042
|
-0.125x |
|
AECC Aero Science and Technology Co Ltd
SHG:600391
|
0.149x |
Annual Cash Flow Conversion Efficiency for Henan Lingrui Pharmaceutical Co Ltd (1999–2024)
The table below shows the annual cash flow conversion efficiency of Henan Lingrui Pharmaceutical Co Ltd from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Henan Lingrui Pharmaceutical Co Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CN¥3.08 Billion ≈ $450.74 Million |
CN¥875.86 Million ≈ $128.17 Million |
0.284x | -2.17% |
| 2023-12-31 | CN¥2.80 Billion ≈ $409.54 Million |
CN¥813.43 Million ≈ $119.03 Million |
0.291x | -10.94% |
| 2022-12-31 | CN¥2.56 Billion ≈ $374.38 Million |
CN¥834.91 Million ≈ $122.17 Million |
0.326x | -11.77% |
| 2021-12-31 | CN¥2.29 Billion ≈ $334.60 Million |
CN¥845.69 Million ≈ $123.75 Million |
0.370x | +90.63% |
| 2020-12-31 | CN¥2.32 Billion ≈ $339.80 Million |
CN¥450.53 Million ≈ $65.93 Million |
0.194x | -4.30% |
| 2019-12-31 | CN¥2.22 Billion ≈ $324.92 Million |
CN¥450.15 Million ≈ $65.87 Million |
0.203x | -2.67% |
| 2018-12-31 | CN¥2.09 Billion ≈ $306.49 Million |
CN¥436.25 Million ≈ $63.84 Million |
0.208x | +333.20% |
| 2017-12-31 | CN¥2.20 Billion ≈ $322.52 Million |
CN¥105.97 Million ≈ $15.51 Million |
0.048x | +60.53% |
| 2016-12-31 | CN¥2.11 Billion ≈ $309.08 Million |
CN¥63.26 Million ≈ $9.26 Million |
0.030x | -67.07% |
| 2015-12-31 | CN¥1.72 Billion ≈ $252.28 Million |
CN¥156.82 Million ≈ $22.95 Million |
0.091x | +14.19% |
| 2014-12-31 | CN¥1.56 Billion ≈ $228.39 Million |
CN¥124.32 Million ≈ $18.19 Million |
0.080x | -38.36% |
| 2013-12-31 | CN¥984.89 Million ≈ $144.12 Million |
CN¥127.27 Million ≈ $18.62 Million |
0.129x | +483.53% |
| 2012-12-31 | CN¥696.97 Million ≈ $101.99 Million |
CN¥15.43 Million ≈ $2.26 Million |
0.022x | -62.59% |
| 2011-12-31 | CN¥684.01 Million ≈ $100.09 Million |
CN¥40.49 Million ≈ $5.92 Million |
0.059x | +1163.14% |
| 2010-12-31 | CN¥709.69 Million ≈ $103.85 Million |
CN¥-3.95 Million ≈ $-578.20K |
-0.006x | -102.71% |
| 2009-12-31 | CN¥645.69 Million ≈ $94.48 Million |
CN¥132.61 Million ≈ $19.40 Million |
0.205x | +158.23% |
| 2008-12-31 | CN¥549.72 Million ≈ $80.44 Million |
CN¥43.72 Million ≈ $6.40 Million |
0.080x | +188.20% |
| 2007-12-31 | CN¥579.24 Million ≈ $84.76 Million |
CN¥15.99 Million ≈ $2.34 Million |
0.028x | -49.82% |
| 2006-12-31 | CN¥486.67 Million ≈ $71.21 Million |
CN¥26.76 Million ≈ $3.92 Million |
0.055x | -21.07% |
| 2005-12-31 | CN¥479.80 Million ≈ $70.21 Million |
CN¥33.43 Million ≈ $4.89 Million |
0.070x | -7.89% |
| 2004-12-31 | CN¥469.45 Million ≈ $68.70 Million |
CN¥35.51 Million ≈ $5.20 Million |
0.076x | +43.63% |
| 2003-12-31 | CN¥451.69 Million ≈ $66.10 Million |
CN¥23.79 Million ≈ $3.48 Million |
0.053x | -68.38% |
| 2002-12-31 | CN¥416.74 Million ≈ $60.98 Million |
CN¥69.41 Million ≈ $10.16 Million |
0.167x | +1861.90% |
| 2001-12-31 | CN¥401.79 Million ≈ $58.79 Million |
CN¥3.41 Million ≈ $499.14K |
0.008x | -5.34% |
| 2000-12-31 | CN¥408.46 Million ≈ $59.77 Million |
CN¥3.66 Million ≈ $536.06K |
0.009x | -88.42% |
| 1999-12-31 | CN¥62.08 Million ≈ $9.08 Million |
CN¥4.81 Million ≈ $703.65K |
0.077x | -- |
About Henan Lingrui Pharmaceutical Co Ltd
Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Pharmaceutical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orth… Read more